Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Open access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 182 papers, 12 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
182citing papers in PubMed, 12 pooled it
82.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
182 citing papers in PubMed, 12 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Immunotherapy in advanced gastroesophageal cancers: A meta-analysis of sex-based outcomes in overall survival.International journal of cancer · 2026Pooled it
- Impact of metastatic pattern and histologic subtype on PD-(L)1 inhibitor efficacy in HER2-negative advanced gastric and gastroesophageal cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Gastric Carcinoma: Diagnosis, Staging, and Treatment.Deutsches Arzteblatt international · 2026Guideline
- What determines value? Exploring value characteristics of novel therapies for digestive system cancers.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma: a single-arm meta-analysis.Frontiers in immunology · 2026Pooled it
- Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- The efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone in advanced or metastatic gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.European journal of clinical pharmacology · 2025Pooled it
- Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy.Cancer immunology, immunotherapy : CII · 2025Pooled it
- First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials.Frontiers in immunology · 2025Pooled it
- Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).Journal of gastric cancer · 2025Guideline
- Efficacy and safety of Nivolumab in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized controlled trials.BMC gastroenterology · 2024Pooled it
- SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).Cancer research and treatment · 2026Trial
- Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up.Advances in therapy · 2026Trial
- Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.Nature medicine · 2025Trial
- Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Trial
- Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.British journal of cancer · 2025Trial
- Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.Journal of surgical oncology · 2025Trial
- First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.Nature medicine · 2025Trial
- Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Trial
122 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 20 institutions in 12 countries.
Yelena Y JanjigianMemorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.ORCID 0000-0002-5357-5858
Jaffer A AjaniThe University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9946-0629
Markus MoehlerJohannes-Gutenberg University Clinic, Mainz, Germany.ORCID 0000-0003-4071-8562
Lin ShenPeking University Cancer Hospital & Institute, Beijing, China.ORCID 0000-0002-8798-4756
Marcelo GarridoClinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile.ORCID 0000-0001-8905-8986
Carlos GallardoFundación Arturo López Pérez, Providencia, Chile.ORCID 0000-0001-6516-395X
Lucjan WyrwiczKlinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland.ORCID 0000-0003-0808-6892
Kensei YamaguchiThe Cancer Institute Hospital of JFCR, Tokyo, Japan.ORCID 0000-0001-6887-5709
James M ClearyDana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7213-3951
Elena ElimovaPrincess Margaret Cancer Centre, Toronto, Canada.
Michalis KaramouzisLaiko General Hospital of Athens, Athens, Greece.ORCID 0000-0003-1369-8201
Ricardo BrugesInstituto Nacional de Cancerologia, Bogotá, Colombia.
Tomasz SkoczylasII Klinika Chirurgii Ogólnej, Gastroenterologicznej i Nowotworów Układu Pokarmowego, Medical University of Lublin, Lublin, Poland.
Arinilda BragagnoliFundacao Pio Xii Hosp Cancer De Barretos, Barretos, Brazil.
Tianshi LiuZhongshan Hospital Fudan University, Shanghai, China.
Mustapha TehfeOncology Center, Centre Hospitalier de l'Universite de Montreal, Montreal, Canada.ORCID 0000-0002-1380-5110
Thomas ZanderUniversity Hospital of Cologne, Cologne, Germany.ORCID 0000-0002-4266-6818
Ruben KowalyszynClinica Viedma S.A., Viedma, Argentina.ORCID 0000-0003-2672-7913
Roberto Pazo-CidHospital Universitario Miguel Servet, Zaragoza, Spain.ORCID 0000-0002-8026-7391
Michael SchenkerSF Nectarie Oncology Center, Craiova, Dolj, Romania.ORCID 0000-0003-2645-6391
Kynan FeenySt John of God Murdoch Hospital, Murdoch, Australia.
Rui WangBristol Myers Squibb, Princeton, NJ.
Ming LeiBristol Myers Squibb, Princeton, NJ.
Clara ChenBristol Myers Squibb, Princeton, NJ.
Raheel NathaniBristol Myers Squibb, Princeton, NJ.
Kohei ShitaraNational Cancer Center Hospital East, Kashiwa, Japan.ORCID 0000-0001-5196-3630
Bristol-Myers Squibb (United States) · USCentre Hospitalier de l’Université de Montréal · CACentrum Onkologii · PLDana-Farber Cancer Institute · USFundación Arturo López Pérez · CLHospital de Câncer de Barretos · BRHospital Universitario Miguel Servet · ESInstituto Nacional de Cancerología · COJohannes Gutenberg University Mainz · DELaiko General Hospital of Athens · GRMedical University of Lublin · PLMemorial Sloan Kettering Cancer Center · USNational Cancer Center Hospital East · JPPeking University · CNPrincess Margaret Cancer Centre · CASt John of God Murdoch Hospital · AUSun Yat-sen University · CNThe Cancer Institute Hospital · JPThe University of Texas MD Anderson Cancer Center · USUniversity Hospital Cologne · DE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsEsophagogastric JunctionNivolumabStomach NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedProgression-Free SurvivalNivolumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.